AT
The startup develops neurodegenerative medicines that utilize insights into progranulin and lysosomal biology to enhance cellular health in the brain. Their therapies aim to delay the progression of neurodegenerative diseases and the onset of associated symptoms.
Updated 2 months ago
Funding
$113.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CAPBFunding rounds are not available yet.
Founders
Product
Features
- The startup develops neurodegenerative medicines that utilize insights into progranulin and lysosomal biology to enhance cellular health in the brain. Their therapies aim to delay the progression of neurodegenerative diseases and the onset of associated symptoms.